We evaluated the incremental cost-effectiveness of @entity9229 compared with levodopa monotherapy in @entity1 with early @entity191 ( @entity191 ) in the German healthcare system. The study design was based on cost-effectiveness analysis using a Markov model with a 10-year time horizon. Model input data was based on a clinical trial "Early Treatment of @entity191 with @entity9229 " as well as on cost data of a German hospital/office-based @entity191 network. Direct and indirect medical and nonmedical costs were included. Outcomes were costs, disease stage, cumulative complication incidence, and mortality. An annual discount rate of 5% was applied and the societal perspective was chosen. The target population included @entity1 in Hoehn and Yahr Stages I to III. It was found that the occurrence of motor complications was significantly lower in @entity1 on @entity9229 monotherapy. For @entity1 aged >/=60 years of age, @entity9229 monotherapy was cost effective when considering costs per decreased UPDRS score. Each point decrease in the UPDRS (I-IV) resulted in costs of @entity7634 ;1,031. Incremental costs per additional motor complication-free @entity1 were @entity7634 ;104,400 for @entity1 <60 years of age and @entity7634 ;57,900 for @entity1 >/=60 years of age. In conclusion, this decision-analytic model calculation for @entity191 was based almost entirely on clinical and observed data with a limited number of assumptions. Although costs were higher in @entity1 on @entity9229 , the corresponding cost-effectiveness ratio for @entity9229 was at least as favourable as the ratios for many commonly accepted therapies.

XXXX versus levodopa monotherapy: a decision analysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity7634 :: ('9319', 'Species') :: ['euro'] @entity9229 :: ('MESH:C047047', 'Chemical') :: ['Cabergoline', 'cabergoline'] @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", 'PD']
@entity9229 :: (MESH:C047047,Chemical) :: ['Cabergoline']
